GERSHON W. HEPNER, M.D., M.R.C.P.; ELLIOT S. VESELL, M.D.
The rate of hepatic metabolism of dimethylaminoantipyrine (aminopyrine), which occurs primarily through N-demethylation, was assessed by measurement of the specific activity of 14CO2 excreted in breath samples obtained 2 hours after oral administration of a trace dose of [14C]aminopyrine. The percentage of administered 14C excreted in 14CO2 in 2 hours was 7.0 ± 1.3 (SD)% in control patients, and significantly less (P < 0.01) in patients with portal cirrhosis (2.6 ± 1.2%), fatty liver (4.7 ± 1.1%), hepatitis (2.6 ± 1.4%), and hepatic malignancy (3.5 ± 1.8%). In 16 of 24 subjects with cholestasis not caused by malignant disease the mean 14CO2 excretion was normal. The 14CO2 excretion in patients with portal cirrhosis correlated highly with aminopyrine metabolic clearance rate (r = 0.92), serum albumin (r = 0.75), and retention of bromsulphalein (r = 0.73). Abnormal 14CO2 excretion returned to normal in patients with hepatitis, when the hepatitis resolved. The data suggest that the aminopyrine breath test is a safe, simple, qualitative and quantitative liver function test.
HEPNER GW, VESELL ES. Quantitative Assessment of Hepatic Function by Breath Analysis after Oral Administration of [14C]aminopyrine. Ann Intern Med. ;83:632–638. doi: 10.7326/0003-4819-83-5-632
Download citation file:
Published: Ann Intern Med. 1975;83(5):632-638.
Gastroenterology/Hepatology, Hematology/Oncology, Liver Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use